Thalidomide: A new anticancer drug?

Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, Guido Carillio, Barbara Capaccetti, Angelo Vacca, Aldo Maria Roccaro, Giampietro Gasparini

Research output: Contribution to journalArticle

Abstract

Experimental studies have demonstrated that thalidomide (Thal), a drug developed as a sedative, has antitumoural properties. The possible antitumour mechanisms of action involve: inhibition of angiogenesis, cytokine-mediated pathways, modulation of adhesion molecules, inhibition of cyclooxygenase-2 and stimulation of immuno response. Therefore, Thal is under clinical evaluation in oncology. This paper provides an overview of the data currently available in literature regarding, in terms of activity and toxicity, the use of Thal in cancer patients. Multiple myeloma is so far the most responsive malignancy. A moderate activity has been documented in certain solid tumours: glioblastoma multiforme, renal cell carcinoma and malignant melanoma. Tolerability is generally satisfactory with peripheral neuropathy being the most relevant dose-dependent toxicity. The more frequent, but moderate side effects are: somnolence, constipation, dizziness and fatigue. More studies are needed to properly evaluate the anticancer activity of Thal alone or in combination with other anticancer treatments. Preliminary studies suggest promising results of Thal in combinations with corticosteroids and cytotoxic drugs as front-line therapy of multiple myeloma. Regarding therapy of solid tumours in the adult, combination with chemotherapy, radiation therapy and molecular-targeting compounds are under investigation.

Original languageEnglish
Pages (from-to)1211-1225
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Thalidomide
Pharmaceutical Preparations
Multiple Myeloma
Neoplasms
Dizziness
Peripheral Nervous System Diseases
Cyclooxygenase 2
Constipation
Glioblastoma
Combination Drug Therapy
Hypnotics and Sedatives
Renal Cell Carcinoma
Fatigue
Melanoma
Adrenal Cortex Hormones
Radiotherapy
Therapeutics
Cytokines

Keywords

  • Angiogenesis
  • Anticancer therapy
  • Biological treatment
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fanelli, M., Sarmiento, R., Gattuso, D., Carillio, G., Capaccetti, B., Vacca, A., ... Gasparini, G. (2003). Thalidomide: A new anticancer drug? Expert Opinion on Investigational Drugs, 12(7), 1211-1225. https://doi.org/10.1517/eoid.12.7.1211.21760

Thalidomide : A new anticancer drug? / Fanelli, Massimo; Sarmiento, Roberta; Gattuso, Domenico; Carillio, Guido; Capaccetti, Barbara; Vacca, Angelo; Roccaro, Aldo Maria; Gasparini, Giampietro.

In: Expert Opinion on Investigational Drugs, Vol. 12, No. 7, 01.07.2003, p. 1211-1225.

Research output: Contribution to journalArticle

Fanelli, M, Sarmiento, R, Gattuso, D, Carillio, G, Capaccetti, B, Vacca, A, Roccaro, AM & Gasparini, G 2003, 'Thalidomide: A new anticancer drug?', Expert Opinion on Investigational Drugs, vol. 12, no. 7, pp. 1211-1225. https://doi.org/10.1517/eoid.12.7.1211.21760
Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A et al. Thalidomide: A new anticancer drug? Expert Opinion on Investigational Drugs. 2003 Jul 1;12(7):1211-1225. https://doi.org/10.1517/eoid.12.7.1211.21760
Fanelli, Massimo ; Sarmiento, Roberta ; Gattuso, Domenico ; Carillio, Guido ; Capaccetti, Barbara ; Vacca, Angelo ; Roccaro, Aldo Maria ; Gasparini, Giampietro. / Thalidomide : A new anticancer drug?. In: Expert Opinion on Investigational Drugs. 2003 ; Vol. 12, No. 7. pp. 1211-1225.
@article{7ac1436ca9884579a60ddd5b75d14f6d,
title = "Thalidomide: A new anticancer drug?",
abstract = "Experimental studies have demonstrated that thalidomide (Thal), a drug developed as a sedative, has antitumoural properties. The possible antitumour mechanisms of action involve: inhibition of angiogenesis, cytokine-mediated pathways, modulation of adhesion molecules, inhibition of cyclooxygenase-2 and stimulation of immuno response. Therefore, Thal is under clinical evaluation in oncology. This paper provides an overview of the data currently available in literature regarding, in terms of activity and toxicity, the use of Thal in cancer patients. Multiple myeloma is so far the most responsive malignancy. A moderate activity has been documented in certain solid tumours: glioblastoma multiforme, renal cell carcinoma and malignant melanoma. Tolerability is generally satisfactory with peripheral neuropathy being the most relevant dose-dependent toxicity. The more frequent, but moderate side effects are: somnolence, constipation, dizziness and fatigue. More studies are needed to properly evaluate the anticancer activity of Thal alone or in combination with other anticancer treatments. Preliminary studies suggest promising results of Thal in combinations with corticosteroids and cytotoxic drugs as front-line therapy of multiple myeloma. Regarding therapy of solid tumours in the adult, combination with chemotherapy, radiation therapy and molecular-targeting compounds are under investigation.",
keywords = "Angiogenesis, Anticancer therapy, Biological treatment, Thalidomide",
author = "Massimo Fanelli and Roberta Sarmiento and Domenico Gattuso and Guido Carillio and Barbara Capaccetti and Angelo Vacca and Roccaro, {Aldo Maria} and Giampietro Gasparini",
year = "2003",
month = "7",
day = "1",
doi = "10.1517/eoid.12.7.1211.21760",
language = "English",
volume = "12",
pages = "1211--1225",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Thalidomide

T2 - A new anticancer drug?

AU - Fanelli, Massimo

AU - Sarmiento, Roberta

AU - Gattuso, Domenico

AU - Carillio, Guido

AU - Capaccetti, Barbara

AU - Vacca, Angelo

AU - Roccaro, Aldo Maria

AU - Gasparini, Giampietro

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Experimental studies have demonstrated that thalidomide (Thal), a drug developed as a sedative, has antitumoural properties. The possible antitumour mechanisms of action involve: inhibition of angiogenesis, cytokine-mediated pathways, modulation of adhesion molecules, inhibition of cyclooxygenase-2 and stimulation of immuno response. Therefore, Thal is under clinical evaluation in oncology. This paper provides an overview of the data currently available in literature regarding, in terms of activity and toxicity, the use of Thal in cancer patients. Multiple myeloma is so far the most responsive malignancy. A moderate activity has been documented in certain solid tumours: glioblastoma multiforme, renal cell carcinoma and malignant melanoma. Tolerability is generally satisfactory with peripheral neuropathy being the most relevant dose-dependent toxicity. The more frequent, but moderate side effects are: somnolence, constipation, dizziness and fatigue. More studies are needed to properly evaluate the anticancer activity of Thal alone or in combination with other anticancer treatments. Preliminary studies suggest promising results of Thal in combinations with corticosteroids and cytotoxic drugs as front-line therapy of multiple myeloma. Regarding therapy of solid tumours in the adult, combination with chemotherapy, radiation therapy and molecular-targeting compounds are under investigation.

AB - Experimental studies have demonstrated that thalidomide (Thal), a drug developed as a sedative, has antitumoural properties. The possible antitumour mechanisms of action involve: inhibition of angiogenesis, cytokine-mediated pathways, modulation of adhesion molecules, inhibition of cyclooxygenase-2 and stimulation of immuno response. Therefore, Thal is under clinical evaluation in oncology. This paper provides an overview of the data currently available in literature regarding, in terms of activity and toxicity, the use of Thal in cancer patients. Multiple myeloma is so far the most responsive malignancy. A moderate activity has been documented in certain solid tumours: glioblastoma multiforme, renal cell carcinoma and malignant melanoma. Tolerability is generally satisfactory with peripheral neuropathy being the most relevant dose-dependent toxicity. The more frequent, but moderate side effects are: somnolence, constipation, dizziness and fatigue. More studies are needed to properly evaluate the anticancer activity of Thal alone or in combination with other anticancer treatments. Preliminary studies suggest promising results of Thal in combinations with corticosteroids and cytotoxic drugs as front-line therapy of multiple myeloma. Regarding therapy of solid tumours in the adult, combination with chemotherapy, radiation therapy and molecular-targeting compounds are under investigation.

KW - Angiogenesis

KW - Anticancer therapy

KW - Biological treatment

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0038445682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038445682&partnerID=8YFLogxK

U2 - 10.1517/eoid.12.7.1211.21760

DO - 10.1517/eoid.12.7.1211.21760

M3 - Article

C2 - 12831355

AN - SCOPUS:0038445682

VL - 12

SP - 1211

EP - 1225

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 7

ER -